Carbon-11 Labeled Sarcosine in Prostate Cancer

University of Michigan

Status: Completed

Conditions: Prostate Cancer

Treatments: Drug: 11C-choline; Drug: 11C-sarcosine

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT02462447

R21CA191052-01 (U.S. NIH Grant/Contract)

HUM00091201

Details and patient eligibility

About

Men with and without prostate cancer will have a PET/CT scan that measures the level of the amino acid sarcosine. PET is a scanning method that uses short lived radioactivity.

Full description

Tissue levels of the amino acid sarcosine are elevated in prostate cancer compared to normal prostate tissues and further increased in metastases from prostate cancer. This research project is designed to test whether 11C-sarcosine (a chemical that is linked to short lived radioactivity) would be useful to detect prostate cancer in men using PET/CT imaging. The uptake and distribution of 11C-sarcosine in men with known or suspected prostate cancer will be determined and compared with results from 11C-choline PET/CT.

Enrollment: 20 patients

Sex: Male

Ages: 40+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males 40 years of age or older
• Confirmed or suspected prostate cancer and will undergo a planned tissue biopsy of the known or suspected tumor (Prostate Cancer Group 1 only)

Exclusion criteria

• Active malignancy (except basal cell or squamous cell skin cancer) within the last 2 years
• Body weight > 350 lbs (158 kg)
• Prisoners
• Subject not willing or able to sign informed consent

Trial design

20 participants in 2 patient groups

Prostate Cancer

Description:

Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.

Treatment:

Drug: 11C-choline

Drug: 11C-sarcosine

Healthy Volunteer

Description:

Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.

Treatment:

Drug: 11C-sarcosine